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Abstract: Here we used solid-phase methods to prepare oligonucleotides carrying fibrin/ 
filaggrin citrullinated peptides. Post-synthetic conjugation protocols were successfully 
applied for the synthesis of oligonucleotides carrying small peptides. A stepwise protocol 
using acid treatment for the final deprotection allowed the preparation of polypyrimidine 
oligonucleotides carrying longer and arginine-rich peptides. An ELISA-based test using  
the oligonucleotide-citrullinated peptide conjugates was developed for the detection of  
anti-citrullinated protein/peptide antibodies in human serum from rheumatoid  
arthritis patients. 
Keywords: oligonucleotide-peptide conjugates; ELISA; solid-phase synthesis; rheumatoid 
arthritis; epitopes; anti-citrullinated protein/peptide antibodies; ACPA; fibrin; filaggrin; 
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1. Introduction 
Oligonucleotide-peptide conjugates (OPCs) are chimeric molecules composed of a nucleic acid 
moiety covalently linked to a peptide moiety. Covalent attachment of peptides to oligonucleotides has 
received considerable attention because of the potential applications of these constructs in fields 
ranging from therapeutics to nanotechnology. For example, oligonucleotides have been attached to a 
number of peptides to enhance the cellular membrane permeability [1–3] and to study the molecular 
requirements for enzyme activity [4]. In addition, OPCs have been used in several sensing systems [5]. 
When conjugated to peptides, oligonucleotides are more resistant to nucleases [6] than when 
unmodified and when linked to cationic peptides, they accelerate duplex formation [7]. 
To date, several protocols for the chemical synthesis of OPCs have been described [8–12]. 
Conjugation of these large and functionalized molecules is a difficult task and often hindered by 
several side-reactions. However, these problems are mainly solved by protecting non-participating 
functional groups or by modifying both peptides and oligonucleotides with additional functional 
groups to form the desired bonds between them. The two most popular synthetic approaches are 
stepwise solid-phase synthesis protocols and the post-synthetic coupling of separately prepared peptide 
and oligonucleotide fragments. 
In the stepwise solid-phase protocols, the peptide and oligonucleotide fragments are usually 
assembled sequentially on the same solid support. Unfortunately, the chemistries of peptide and 
oligonucleotide synthesis are not compatible, thus modifications of standard protecting groups or 
activating and deblocking agents are required [13]. In general the peptide moiety is synthesized first 
using tert-butoxycarbonyl (Boc)-amino acids with side chains protected with base-labile groups such 
as trifluoroacetyl (TFA) or 9-fluorenylmethoxycarbonyl (Fmoc) groups. The oligonucleotide sequence 
is then assembled using standard DNA synthesis protocols. 
Post-synthetic coupling in solution is accomplished by chemoselective ligation mediated by 
mutually reactive groups that are introduced into the oligonucleotides and peptides. This strategy 
includes the formation of several linkages such as disulfide, amide, oxime, thiazolidine, urea and 
carbonyl linkages, or Diels-Alder or Hüisgen 1,3-dipolar cycloaddition reactions [12]. 
Despite the above methods, versatile and high yielding methods are still required for the synthesis 
of OPCs. Solid-phase methods for the preparation of these conjugates offer the advantage that the 
excess of reagents is removed easily by filtration and only one single purification step at the end of the 
synthesis is needed. However, these methods are not extensively used as they call for synthesizers, and 
the efficiency of the synthesis may be low in the case of long or difficult peptides. Recently, a method 
for the efficient solid phase conjugation of commercial peptides and oligonucleotides was reported [14]. 
Moreover, protection of the side chain of arginine with a base-labile group is complex; however, two 
methods have been described: the di-Fmoc derivative of arginine [15] and the introduction of ornithine 
followed by post-synthetic guanidylation of ornithine to arginine [16]. 
Peptides are used in the diagnosis of several human diseases. Synthetic peptides have been shown to 
be valuable tools for laboratory diagnosis and can provide uniform, chemically well-defined antigens 
for antibody analysis, thereby reducing inter- and intra-assay variation. The main aim in the 
development of peptide-based diagnostic tests is to achieve recognition of specific antibodies induced 
by whole viral proteins but using selected short fragments containing the most potent antigenic 
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determinants. The success of this approach depends on the extent to which synthetic peptides mimic 
the immunodominant epitopes of antigens. In recent years, synthetic peptides that mimic specific 
epitopes of the proteins of infectious agents have been used in diagnostic systems for various human 
diseases [17]. 
Regarding rheumatoid arthritis (RA), a common autoimmune disease characterized by chronic 
inflammation of the synovial joints, citrullinated peptides have been successfully used for the detection 
of anti-citrullinated protein/peptide antibodies (ACPAs), the most specific serologic markers of this 
desease [18]. Citrullination is a post-transcriptional modification of proteins, in which a positively 
charged Arg is deiminated and converted into a neutral amino acid (citrulline) by means of 
peptidylarginine deiminases [19]. 
ACPAs can be detected by using enzyme-linked immunosorbent assays (ELISAs) with different 
citrullinated protein or peptide antigenic substrates. We have designed chimeric and cyclic peptides 
that bear various citrullinated peptide sequences within the same molecule [20,21]. Particularly, a 
chimeric fibrin/ filaggrin citrullinated peptide, [Cit630]fibrin(617-631)-S306, S319cyclo[Cys306,319, 
Cit312]filaggrin (304-324) (CFFCP1), containing an -fibrin peptide and the cyclic filaggrin peptide 
(Figure 1), which forms the basis of the commercial CCP1 test [22], is one of the most reactive ACPA 
epitopes [20,21]. 
Figure 1. Amino acid sequence of chimeric fibrin/filaggrin citrullinated peptide 
(CFFCP1). Linear fibrin (p18) is indicated. 
NH2-His-Ser-Thr-Lys-Arg-Gly-His-Ala-Lys-Ser-Arg-Pro-Val-Cit-Gly-His-Gln-Cys
CONH2-Ser-Gly-Ser-Arg-Gly-Cys
His
Gln Glu Ser Thr
Cit
Gly
Arg
SerArgGly
Arg
p18
 
Here we describe the synthesis of oligonucleotide conjugated to CFFCP1. In addition, the synthesis 
of oligonucleotides conjugated to both linear fibrin/ filaggrin [Cit630]fibrin(617-631)-[Cys306,319, 
Cit312]filaggrin (304-324) and linear fibrin [Cit630]fibrin (617-631), sequences is reported. 
These conjugates are bound either directly or through complementary oligonucleotides to surfaces 
to design potential ELISAs to determine the presence of ACPAs in human serum. The oligonucleotide 
moiety may act as a reversible spacer between the surface and the antigen, thus facilitating the 
functionalization of the surface [23]. This strategy known as DNA-directed immobilization (DDI) [24] 
or oligo-tag [25] provides a chemically mild process for the binding of multiple antigens to a solid 
support, using DNA surfaces as immobilization matrices. This strategy has been used to immobilize 
proteins [26], steroids [23] and glycoconjugates [27–29] onto surfaces for simultaneous detection of 
multiple analytes. 
The synthesis of these conjugates is a challenging task as the CFFCP1 peptide is relatively large  
(36 amino acids) and contains five arginine and two citrulline residues and a disulfide bond. The 
synthesis of these conjugates was attempted following post-synthetic or solid-phase protocols.  
Post-synthetic conjugation protocols were successfully applied to synthesize the oligonucleotide-linear 
fibrin peptide conjugate but were not efficient for the synthesis of the longer oligonucleotide-chimeric 
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peptide conjugates. A new protocol for the stepwise synthesis of oligonucleotide-linear fibrin peptide 
conjugates using an acidic treatment for the final deprotection step is described, as the presence of  
five arginines in the peptide sequence precludes the use of the base-labile protecting groups [8–12]. In 
addition, the formation of the disulfide bond between the two cysteine residues of CFFCP1 was 
assessed after removal of the oligonucleotide-peptide conjugate from the solid support. Furthermore, 
we prepared several conjugates in which the two cysteines of the peptide were substituted by two 
serines and evaluated in an ELISA. Finally, an ELISA-based assay was used for the detection of 
ACPAs in RA patient sera. To this end, and to avoid unpredictable orientation on the surface, OPC 
immobilization on the microwell surface was achieved using oligonucleotides carrying amino or thiol 
groups. ACPA-OPC binding was analyzed using a well-established peroxidase-based colorimetric 
assay [20,21]. 
2. Results and Discussion 
2.1. Synthesis of OPCs via Post-Synthetic Method 
The synthesis of OPCs is a difficult task, especially when the peptides or oligonucleotides involved 
are large. The preparation of these conjugates is hindered by the fact that the protection schemes used 
in the synthesis of these molecules are not compatible. For example, standard protective groups in 
solid-phase peptide synthesis require acidic conditions for their removal, which may cause the loss of 
the nucleobases, especially in purines (depurination). On the other hand, oligonucleotides are usually 
prepared in basic conditions, which may hydrolize peptide bonds or cause unwanted side-reactions, 
such as racemization. The incompatibility between peptides and oligonucleotides can be circumvented 
by preparing the two components separately using standard peptide and oligonucleotide synthetic 
methods and afterwards linking them. Nevertheless, selectivity between reactive functional groups of 
these two components is not always accomplished, and several side reactions may occur. In addition, 
the secondary structure of these biomolecules may prevent the conjugation reaction. 
The peptides carrying a maleimido group used in this study were synthesized following the Fmoc/ 
tert-butyl (t-Bu) strategy [30]. CFFCP1 peptide was also prepared in linear form, the two cysteines 
being protected with an acetamido group. Once the assembly of the peptide sequences was completed, 
cleavage and deprotection of the resulting peptide supports was carried out using the usual acid 
treatment (TFA). The peptides were isolated by precipitation, purified by analytical HPLC, and 
characterized by electrospray mass spectrometry. Disulfide bond formation was accomplished by 
removing acetamido groups in the presence of iodine in acidic conditions. The resulting cyclic CFFCP1 
peptide carrying the maleimido group was isolated by HPLC and characterized by mass spectrometry. 
Two oligonucleotides containing a hexyl thiol group at the 5′-end were prepared. The first  
synthesis was an octathymidine oligonucleotide and the second the 20-mer sequence  
(5′-TACATGCGTGCTGATGCAAG-3′). 
Maleimido-peptides were reacted with thiolated oligonucleotides (Figure 2), and the expected 
conjugates were isolated by HPLC and characterized by mass spectrometry. Moderate yields of the 
short OPC were obtained following this strategy, but conjugation of the 20mer sequence with cyclic 
peptide CFFCP1 was unsuccessful. Maleimido–thiol linkage is commonly used to connect short 
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peptides to oligonucleotides; however, some problems have been reported for complex peptides. For 
example, a decrease in efficiency has been described with hydrophobic peptides that are not highly 
soluble in aqueous solvents [11]. Also, low yields have been observed during the conjugation of 
oligonucleotides to highly structured peptides with several positive charges [11]. In our case, during 
the HPLC purification of the reaction between the maleimido-CFFCP1 cyclic peptide and  
thiol-oligonucleotides, we observed conversion of the OPC to the starting thiol-oligonucleotide and 
maleimido-peptide by a retro-Michael reaction. This reaction was also detected in a conjugate of an 
oligonucleotide with a long peptide [31], but the degradation of the conjugates was not as rapid  
as observed during the conjugation to CFFCP1. To obtain the desired conjugates, we followed the 
solid-phase strategy. 
Figure 2. Synthesis of OPCs using maleimido-peptides and thiol-oligonucleotides 
following the post-synthetic conjugation protocol. 
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2.2. Synthesis of Linear OPCs via Solid-Phase Method 
Most of the solid-phase methods reported for OPC synthesis contain the peptide moiety at the  
3′-end of the oligonucleotide [32–34]. In these strategies, the peptide is first synthesized and then the 
oligonucleotide is assembled in the peptidyl resin. Two types of N-protected amino acids can be used. 
First, the N--Boc-amino acids containing base-labile protecting groups (Fmoc, Fm, Tfa, Tos, Dnp) 
for the protection of trifunctional amino acid side chains. These groups can be removed concomitantly 
with the nucleotide protecting groups after the completion of OPC synthesis [32,33]. The second 
strategy uses Fmoc-amino acids containing acid-labile (t-Bu) groups for the protection of trifunctional 
amino acid side chains. The t-Bu groups are removed without the presence of the oligonucleotide. 
Several authors have also proposed various amino acid side chain protecting groups that can be 
removed in mild conditions [12]. As CFFCP1 peptide has five arginines, which have no satisfactory 
side chain protecting group that can be removed in basic conditions, we tested a new protocol for the 
stepwise synthesis of OPCs using an acid treatment for the final deprotection step. In this way, the 
standard Fmo/t-Bu strategy was used to synthesize the peptide; however, this method requires the use 
of TFA in the presence of the oligonucleotide, which may induce depurination. Although some  
authors have described the isolation of OPCs after TFA treatment [34], we found that purine  
2′-deoxynucleotides are not stable to TFA [35]. For this reason the method may be restricted to 
polypyrimidine sequences [35,36]. 
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Syntheses of OPCs carrying p18 and CFFCP1 sequences were carried out following the Fmoc/t-Bu 
strategy (Figure 3). First, the peptide with acid-labile side chain protection was assembled using the 
following groups for the protection of the side chains of amino acids: triphenylmethyl (Trt) for 
histidine; tert-butyl (t-Bu) for serine and threonine; 2,2,5,7,8-pentamethyl-chroman-6-sulfonyl (Pmc) 
for arginine, tert-butoxycarbonyl (Boc) for lysine and acetamidomethyl (Acm) for cysteine. Then 4-O-
trityl-4-hydroxybutyric acid linker was added to the N-terminal position of the peptide support [10,13]. 
This linker generates a free hydroxyl after the removal of the trityl group, thus allowing assembly of 
the oligonucleotide sequence on a DNA synthesizer. The removal of the trityl group is done at the 
DNA synthesizer using the standard detritylation reagent (2% TCA in dichloromethane). The resulting 
oligonucleotide-peptide support contains protecting groups that are removed with bases (nucleobases 
and phosphate groups) and with acids (amino acid side chain protecting groups and removal of the 
OPC from the solid support). The order of these treatments was assayed on a model sequence. 
Octathymidinyl-CFFCP1 linear OPC (OPC-4) was obtained following both protocols. First, we used 
ammonia followed by TFA treatment in the presence of scavengers. The second protocol consisted of 
the deprotection of the OPC with TFA, followed by ammonia treatment. The Acm groups are stable to 
oligonucleotide and peptide synthesis conditions obtaining the OPC carrying Cys(Acm) residues. The 
conjugates were purified by HPLC and analyzed by mass spectrometry (Table 1). Both protocols gave 
the desired conjugate as a major product but the yield was higher in the first. Nevertheless, this method 
allows the synthesis of only pyrimidine sequences, as these are stable to TFA [35,36]. 
Figure 3. Synthesis of OPCs using the stepwise solid-phase method. 
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Table 1. Oligonucleotide peptide conjugates prepared in this study. 
Name Method Sequence CPeptideN-link-(5′-3′) MS 
(expected) 
MS 
(found) 
OPC-1 PSC p18-X-TTTTTTTT 4438 4435 
OPC-2 PSC p18-X-TACATGCGTGCTGATGCAAG 8211 8208 
OPC-3 PSC (CFFCP1)-X-TACATGCGTGCTGATGCAAG 10673 10677 
OPC-4 SSPS (CFFCP1 linear)-Y-TTTTTTTT  6687 6688 
OPC-5 SSPS (CFFCP1 linear)-Y-TCTCTCTCTCTC 7814 7820 
OPC-6 SSPS (CFFCP1 linear)-Y-TTTTTTTTTTTT  7904 7910 
OPC-7 SSPS (CFFCP1)-Y-TTTTTTTTTTTT 7759 7765 
OPC-8 SSPS (CFFCP1Ser )-Y-TTCTTTTCTCTT 7684 7686 
OPC-9 SSPS (CFFCP1Ser )-Y-UUCUUUUCUCUU 7918 7914 
C, U are 2′-O-methyl-RNA nucleotides; X is the maleimido-thiol linkage; Y is the 4-hydroxybutanoic linker; 
PSC stands for post-synthetic conjugation; SSPS stands for stepwise solid-phase synthesis; p18 is NHis-Ser-
Thr-Lys-Arg-Gly-His-Ala-Lys-Ser-Arg-Pro-Val-Cit-GlyC-CONH2; CFFCP1 is shown in Figure 1. CFFCP1 
linear is NHis-Ser-Thr-Lys-Arg-Gly-His-Ala-Lys-Ser-Arg-Pro-Val-Cit-Gly-His-Gln-Cys(Acm)-His-Gln-Glu-
Ser-Thr-Cit-Gly-Arg-Ser-Arg-Gly-Arg-Cys(Acm)-Gly-Arg-Ser-Gly-SerC-CONH2; CFFCP1Ser is NHis-Ser-
Thr-Lys-Arg-Gly-His-Ala-Lys-Ser-Arg-Pro-Val-Cit-Gly-His-Gln-Ser-His-Gln-Glu-Ser-Thr-Cit-Gly-Arg-Ser- 
Arg-Gly-Arg-Ser-Gly-Arg-Ser-Gly-SerC-CONH2. 
OPC-8 and -9 were prepared following a solid-phase method. As an example, in Figure 4 is shown 
the HPLC profile of OPC-8. A new peptide (CFFCP1Ser) was synthesized in which the two Cys are 
substituted for Ser. This linear peptide proved also to recognize ACPAs in human serum from RA 
patients (data not shown), according to results published by Sebbag et al. [37], who described that the 
citrullinated derived peptide of the 306-324 C-terminus of filaggrin with Ser in positions 306 and 319 
was recognized by a high number of RA sera. 
Figure 4. HPLC profile obtained after the synthesis of OPC-8 (CFFCP1Ser)-Y-
TTCTTTTCTCTT). Detection wavelength 260 nm. 
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After the addition of the 4-hydroxybutanoic linker, two sequences were assembled in CFFCP1Ser 
peptidyl solid support. The first was a DNA sequence containing dC and T derivatives (OPC-8) and 
the second is an RNA containing 2′-O-methyl-C and 2′-O-methyl-U derivatives with the same 
sequence (OPC-9). These two conjugates were deprotected using ammonia followed by the TFA 
protocol and used for the immunological test of RA. 
2.3. Synthesis of Cyclic Peptide Oligonucleotide Conjugate Using the Solid-Phase Method 
The strategy of peptide cyclization has been described for designing citrullinated peptides with 
higher affinity for the ACPA. The cystine-bridged cyclic peptides led to far better results in RA 
diagnosis than the linear counterparts [22]. 
OPC-7 corresponds to a cyclic conjugate of OPC-6. To our knowledge, this is the first time that  
the synthesis of a cyclic peptide has been attempted while covalently attached to an oligonucleotide. 
The formation of the disulfide bond was carried out as described for the cyclization of linear  
CFFCP1-peptide [20]. Specifically, Acm protecting groups of the Cys of OPC-6 were removed in the 
presence of I2 in acidic conditions and quenched by ascorbic acid. Finally, cyclic OPC was purified by 
HPLC (Figure 5) and characterized by mass spectrometry. The overall yield of cyclic OPC synthesis 
was low, nevertheless we were able to isolate the correct cyclic OPC for the T12 sequence. 
Figure 5. HPLC profile obtained after the synthesis of OPC-7 (CFFCP1-Y-T12). Detection 
wavelength 260 nm. 
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2.4. Enzyme-linked immunosorbent assays of OPCs 
In addition to citrullinated proteins such as filaggrin, fibrin and vimentin, several synthetic citrullinated 
peptides have been used as antigenic substrates in serological tests for the diagnosis of RA [17]. We 
considered the linear peptide CFFCP1Ser and we have prepared and evaluated OPC-8 and OPC-9 in 
ELISAs for the detection of ACPAs present in the human serum of RA patients. We analyzed two 
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ELISA formats. The first one was based on the binding of a single OPC to the ELISA plate (Figure 6A). 
While the second was based on a duplex format in which a single OPC was hybridized with its 
complementary DNA strand and the duplex was attached to the ELISA plate (Figure 6B). 
Figure 6. Schematic representation of two forms of OPC binding. A) Single OPC attached 
to ELISA plate and B) duplex OPC formed by OPCs and their complementary strand, 
which is attached to the ELISA plate through a thiol or an amino group. 
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OPC-8 and OPC-9 gave the same results in both ELISA formats using a peroxidase-based 
colorimetric read-out. Immunological tests were carried out at two concentrations (25 pM and 250 pM 
per well) of single and duplex OPC and two different binding chemistries were used to attach them to 
the surface of ELISA plate. In the first approach we used DNA-BindTM plates (Costar, Corning Inc., 
Corning, NY, USA) coated with reactive N-oxysuccinimide esters, which react with nucleophiles such 
as amines in basic conditions to form amide groups. The single OPCs reacted through free amino 
groups of the peptide sequence whereas in duplex OPCs, in addition to these amino groups the 
complementary DNA strand of OPC contained a free amino in the 5′-end. 
Figure 7 shows the ELISA results of single and duplex OPCs with human serum at 25 pmol/well 
using DNA-BindTM plate. Two serum samples from healthy volunteers (BD1 and BD2) and two from 
ACPA-positive (RA1, RA2) RA patients were analyzed. In these conditions both formats (single OPC 
and duplex OPC) were recognized by ACPAs, although low optical density values were obtained. The 
reactivity of the two RA sera was slightly lower for single format than the duplex OPC. Moreover, 
single OPCs showed higher variability of the intra-assay replicated values. 
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Figure 7. Reactivity of rheumatoid arthritis (RA) and blood donor (BD) sera with single 
and duplex OPC (OPC-8 with its complementary strand 5′AAGAGAAAAGAATTTTT-
NH2 3′). A concentration of 25 pmol/well of each OPC was immobilized via amine groups 
on DNA-BindTM plates. 
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Since the concentration of OPC tested (25 pmol/well) was about 10-fold lower than the peptide 
concentration used in the previously reported ELISAs [10,21], next we tested 250 pmol/well of duplex 
OPC following the same experimental procedure. The reactivity of RA sera was now significantly 
higher, while BD control sera remained low (Figure 8). In these conditions, the differences between 
ACPA-positive and control sera increased significantly although the optical density values were lower 
than those obtained with the peptide-based assay. 
Figure 8. Reactivity of rheumatoid arthritis (RA) and blood donor (BD) sera with duplex 
OPC (OPC-8 with its complementary strand 5′AAGAGAAAAGAATTTTT-NH2 3′). 
Concentration of 25 and 250 pmol/well of duplex OPC-8 was immobilized via amine 
groups on DNA-BindTM plates. 
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With the aim of improving these results, the ELISA procedure assay was modified in order to 
properly present the antigenic sequence of the conjugate for its specific ACPA recognition. To this 
end, an oriented covalent bonding of the duplex OPC to the solid surface by means of a thiol group at 
the 5′-end of its complementary strand was assayed. The immobilization of a concentration of  
250 pmol/well of this duplex was performed in neutral conditions using an ELISA plate Nunc 
ImmobilizerTM (Thermo Scientific, Roskilde, Denmark). These commercial ELISA plates contain a 
stable electrophilic group that reacts with nucleophiles such as free amines, thiols or hydroxy-groups. 
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Reactivity of the amine and thiol groups is a function of pKa and can be modulated by pH. In neutral 
conditions, amines are protonated and are poor nucleophiles because the pH is below their pKa. 
Nevertheless, in neutral conditions thiolate anion is also formed and should be the reactive species. 
Thus, the activated plate should react only with the thiol group at the 5’-end of the complementary 
strand of the duplex OPC. 
Figure 9 shows the comparative results obtained with the amine and thiol immobilization of the 
duplex OPC on the solid surface. Thiol immobilization was more effective than amino immobilization. 
Nevertheless, OPC with a complementary amino strand also gave a positive signal. Although  
OPC immobilization occurs mainly throughout covalent bonding to the activated plate, unspecific  
non-covalent binding should also be assumed. It should be highlighted that the oriented presentation of 
the antigenic sequence of duplex OPC by means of a defined chemical strategy led to a significant 
increase in specific ACPA recognition. 
Figure 9. Reactivity of rheumatoid arthritis (RA) and blood donor (BD) sera with duplex 
OPC. For amine immobilization OPC-8 with its complementary strand 
5′AAGAGAAAAGAATTTTT-NH2 3′ was used while for thiol immobilization OPC-8 
with 5′ AAGAGAAAAGAATTTTT-SH 3′ was used. The peptide CFFCP1Ser was added 
as positive control. A concentration of 250 pmol/well of duplex OPC-8 was immobilized 
on the corresponding ELISA plates. 
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These results demonstrated that the immune recognition of ACPAs present in the human serum of 
RA patients is also possible using OPCs. Optimized conditions were found at 250 pmol and thiol 
immobilization of the duplex OPC. 
Furthermore, we compared the reactivity of the two RA serum samples with the peptide substrate 
(CFFCP1Ser) using the optimized conditions. As illustrated, the recognition of peptide CFFCP1Ser 
was 20–25% higher than that corresponding to OPC8. This enhancement may be attributable to a 
lower binding efficiency of OPC to the ELISA plate or to a lower stability of the oligonucleotide-
peptide conjugate in the ELISA assay. Nevertheless, here we have demonstrated the capacity of OPCs 
to recognize ACPAs present in human serum of RA patients. These antigenic conjugates might be of 
relevance in the development of new nanotechnology-based immunosensors for the specific detection 
of biomarkers with applications in the diagnosis of human diseases. 
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3. Experimental  
3.1. Synthesis of the MBA-p18 and MBA-CFFCP1 Peptide 
The [Cit630]fib(617-631) peptide (p18) and [Cit630]fibrin(617-631)-[Cys306,319, Cit312] 
filaggrin(304-324) peptide (CFFCP1) were synthesized manually as C-terminal carboxamides on a 
Tentagel RAM resin (Rapp Polymere GmbH, Tübingen, Germany) (500 mg, 0.28 meq/g) and 
following a 9-fluorenyl-methoxycarbonyl (Fmoc) strategy. Amino acid side chain protection was 
effected by the following: triphenylmethyl (Trt) for histidine; tert-butyl (t-Bu) for serine and threonine; 
2,2,5,7,8-pentamethyl-chroman-6-sulfonyl (Pmc) for arginine, tert-butoxycarbonyl (Boc) for lysine 
and acetamidomethyl (Acm) for cysteine. 
Sequences were: MBA-p18, maleimido-benzoyl-His-Ser-Thr-Lys-Arg-Gly-His-Ala-Lys-Ser-Arg-
Pro-Val-Cit-Gly-CONH2 and MBA-CFFCP1, maleimido-benzoyl-His-Ser-Thr-Lys-Arg-Gly-His-Ala-
Lys-Ser-Arg-Pro-Val-Cit-Gly-His-Gln-Cys(Acm)-His-Gln-Glu-Ser-Thr-Cit-Gly-Arg-Ser-Arg-Gly-Arg-
Cys(Acm)-Gly-Arg-Ser-Gly-Ser-CONH2. 
The coupling reaction was performed using four-fold molar excesses of activated Fmoc-amino acids 
throughout the synthesis. The amino acids were activated essentially by means of treatment with  
2-(1H-7-azabenzotriazole-1-yl)-1,1,3,3-tetramethyl uronium hexafluorophosphate methanaminium 
(HATU) and a base such as diisopropylethylamine (DIPEA). The Fmoc-deprotection step was done 
twice with 20% piperidine in dimethylformamide (DMF) for 10 min. The efficiency of these reactions 
was evaluated by the ninhydrine colorimetric reaction. 
The peptide sequence was subsequently derivatized in N-terminus with 3-(2,5-dioxo-2,5-dihydro-
pirrol-1-yl)-benzoic acid. The m-maleimidobenzoic acid was incorporated in solid phase by means of 
treatment with N,N′-diisopropylcarbodiimide (DIPCDI) and hydroxybenzotriazole (HOBt). The 
coupling reaction was carried out in duplicate using a three-fold excess of reagents. 
Once the synthesis was completed, the cleavage and deprotection processes of the peptidyl resin 
were carried out by means of treatment with 94% trifluoroacetic acid (TFA) for 4 h in the presence of 
2.5% H2O, 2.5% 1,2-ethanedithiol (EDT) and 1% triisopropylsilane (TIS) as scavengers. 
CFFCP1 peptide was synthesized in its linear form, in which the Cys are protected by Acm groups, 
and in cyclic form, in which the two Cys form a disulfide bond. 
The peptides were isolated by precipitation with cold diethyl ether, centrifuged and lyophilized. 
They were then characterized by analytical HPLC on a Kromasil C-18 column (Teknokroma, San 
Cugat del Vallés, Spain, 5 m, 25 × 0.46 cm) with a linear gradient of 95–5% solvent A in solvent B 
over 20 min at a flow rate of 1 mL/min using 0.05% TFA in water (A) and 0.05% TFA in acetonitrile 
(ACN) (B) as eluting system. The peptide was purified by preparative HPLC in a Kromasil-C8 column 
(Tecknokroma, 5 m, 25 × 2.2 cm) and characterized by Electrospray-Mass Spectrometry (ES-MS, 
positive mode) MBA-p18: [M] = 1872.68 (expected M = 1873.08). MBA-CFFCP1 linear [M] = 4334.76 
(expected M = 4333.20). Electrospray ionization mass spectrometry was performed with a Liquid 
Chromatograph-Time of Flight (LC-TOF) detector, LCT Premier XE (Micromass Waters, Manchester, 
UK) coupled to the UPLC (Waters, Milford, MA, USA). Samples were dissolved in a mixture of 
acetonitrile/water (1:1, v/v) and analyzed previously at the UPLC with a flow rate of 0.3 mL/min. 
Mass spectra were recorded in positive ion mode in the m/z 500–2500 range. 
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3.2. Synthesis of Oligonucleotides 
Oligonucleotides 5′ TTTTTTTT 3′ and 5′ TACATGCGTGCTGATGCAAG 3′ were synthesized in 
a 0.2 µM scale using DNA synthesizer (Applied Biosystems 3400, Foster City, CA, USA). After 
assembly of the sequences, a thiol group was introduced at the 5′-end using thiol modifier C6  
S-S-CE phosphoramidite (Link Technologies, Lanakshire, Scotland). The oligonucleotides were 
deprotected using 1 mL of 33% NH3 and 7 mg of 1,4-dithiothreitol (DTT) for 6 h at 55 °C. After, the 
solution was concentrated desalted on a Sephadex column (NAP-10) prior to use. 
Complementary oligonucleotide of OPC-8 and -9 with a spacer of five thymidines was prepared 
following the same procedure. These sequences were prepared using 3′-Thiol-modifier C3 S-S-CPG 
(Link Technologies) or 3′-Amino-modifier-C7 CPG (Link Technologies) to obtain an amino or thiol 
group at the 3′-end. These sequences were 5′AAGAGAAAAGAATTTTT-NH2 3′ and 
5′AAGAGAAAAGAATTTTT-SH 3′. 
3.3. Synthesis of Linear OPCs Using the Post-Synthetic Method  
The MBA-p18 peptide carrying a maleimido group (0.3 mg) was incubated with 5′-SH-hexyl-
phosphate-TTTTTTTT-3′ (2.4 OD units at 260 nm) in 0.1 M triethylammonium acetate (TEAA) at pH 
7.0 overnight at room temperature. The solution was evaporated to dryness and the mixture analysed 
by HPLC. Column: Nucleosil 120-10 C18 (250 × 4 mm); 20 min linear gradient from 0% to 50% B; 
flow rate 3 mL/min; solution A was 5% ACN in 0.1 M aqueous TEAA and B 70% ACN in 0.1 M 
aqueous TEAA. The starting thiol-oligonucleotide (elution time 9 min) was converted to a new product 
(elution time 10.9) which was collected. For the synthesis of OPC-3, 100 µL of DMF was added to the 
coupling reaction to increase the solubility of the peptide. Column: X-BridgeTM OST C18 (4.6 × 50 mm, 
2.5 µm); 20 min linear gradient from 0% to 20% B followed by an 8 min gradient to 100% B and flow 
rate 1 mL/min; solution A was 5% ACN in 0.1 M aqueous TEAA and B 70% ACN in 0.1 M aqueous 
TEAA. Yields after HPLC purification were 5–10%. Mass spectrometry confirmed the expected mass 
for OPCs. Mass spectrometry (MALDI-TOF, negative mode) analysis: OPC-1 [M] = 4435 (expected 
M = 4438). OPC-2 [M] = 8208 (expected M= 8211). OPC-3 [M] = 10677 (expected M = 10673). OPC-3 
was not stable and decomposed readily to starting thiol-oligonucleotide by a retro-Michael reaction. 
Matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectra were recorded 
either on a Voyager-DE-RP spectrometer (Applied Biosystems) or in a 4800 Plus MALDI TOF/TOF 
(ABSCiex-2010, Flamingham, MA, USA) in negative mode by using 2,4,6-trihidroxyacetophenone 
hydrate (THAP) matrix with ammonium citrate, 50 mg/mL in water as additive). 
3.4. Synthesis of Linear OPCs Using the Solid-Phase Method 
The CFFCP1 peptide and the same peptide in which the two Cys were replaced by Ser 
(CFFCP1Ser) were prepared in solid-phase as described before. Before adding the spacer, we analyzed 
a small amount of the peptide by mass spectrometry (electrospray, positive mode). CFFCP1Ser:  
[M] = 3967.05 (expected M = 3966.28), CFFCP1 linear: [M] = 4141.20 (expected M= 4141.57). Then, 
4-hydroxybutyric acid linker was added to the N-terminal position of the peptide sequence using 
PyBOP, (5-fold excess) and DIEA (10-fold excess) for 1 h. The unreacted amino groups of the 
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resulting support were blocked with acetic anhydride and DIEA. Next, solid-phase oligonucleotide 
synthesis was carried out using this peptide solid support on a DNA synthesizer (Applied Biosystems 
3400). OPCs were prepared using 2-cyanoethyl phosphoramidites of thymidine and 2′-deoxycytidine 
for the OPCs 4,5,6,7,8 and 2-cyanoethyl phosphoramidites of 2′-O-methyluridine and 2′-O-methylcytidine 
for OPC-9. The following solutions were used: 0.4 M 1H-tetrazole in ACN (activation);  
3% trichloroacetic acid in DCM (detritylation), acetic anhydride/pyridine/tetrahydrofuran (1:1:8) 
(capping A), 10% N-methylimidazole in tetrahydrofuran (capping B), 0.02 M iodine in 
tetrahydrofuran/pyridine/water (7:2:1) (oxidation). 
A modified 1 µmol synthesis cycle was used: coupling time was increased to 5 min, capping and 
oxidation to 1 min, and detritylation to 2 min (4 × 30 s). The average coupling yield was around  
97–98% per step for RNA monomers and 99% for DNA monomers. The solid supports were treated 
with 2 mL concentrated aqueous ammonia (three treatments of 30 min each). After that, acidic 
treatment with 95% trifluoroacetic acid (TFA) in the presence of scavengers 2% H2O, 2%  
1,2-ethanedithiol (EDT) and 1% triisopropylsilane (TIS) for 4 h. The OPCs were isolated by 
precipitation with cold diethyl ether, centrifuged and lyophilized. Finally, the conjugates were desalted 
in a Sephadex column (NAP-10) and purified by HPLC as described above. Yields after HPLC 
purification were 10–20%. 
OPC-4 was also obtained using first a TFA treatment and then the residue was treated with 
ammonia. Yields of OPC-4 using ammonia + TFA treatment were twice those achieved with  
TFA + ammonia treatment. The purified products were analyzed by MALDI-TOF (negative mode) 
mass spectrometry (see Table 1 and supplementary material). OPC-4 [M] = 6688 (expected M = 6687); 
OPC-5 [M] = 7820 (expected M = 7814), cal 7814; OPC-6 [M] = 7910 (expected M = 7904); OPC-8 
[M] = 7686 (expected M= 7684); OPC-9 [M] = 7914 (expected M = 7918). 
3.5. Synthesis of Cyclic OPC Using Solid-Phase Method  
T12-CFFCP1 (OPC-7) was prepared as described for linear OPC. Formation of the disulfide bond 
between the two Cys was carried out selectively after the deprotection of Acm protecting group of 
these two Cys. Linear T12-CFFCP1 (0.1 mg) was dissolved in 2 mL of H2O:AcOH (1:1) under N2 
atmosphere, then 600 µL HCl (1 M, 0.1 mL/mg) followed by 300 µL of I2 (0.1 M, 20 eq/Acm) were 
added. After four hours, the iodine was quenched by adding 1 M ascorbic acid drop-wise until the 
mixture become colorless. The solution was then concentrated by evaporation under reduced-pressure 
to approximately one third of the original volume. Finally, the cyclic conjugate was isolated and 
purified by HPLC. Yield after HPLC purification was 2%. MALDI-TOF mass spectrometry OPC-7 
[M] = 7765 (expected M = 7759). 
3.6. Serum Specimens 
Human serum was collected from patients attending the Rheumatology Service at the Hospital 
Clinic in Barcelona. These patients were diagnosed with RA following the revised criteria formulated 
by the American College of Rheumatology and were previously tested for the presence of anti-CCP2 
antibodies by ELISA (Immunoscan RA; Eurodiagnostica, distributed by Diasorin, Madrid, Spain). 
Serum samples used as negative controls were obtained from healthy blood donors at the same hospital. 
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3.7. ELISA Assays 
Immunological assays were performed using ELISA microplates. Single OPCs and duplexes 
formed by annealing with the corresponding complementary sequence containing an amino or a thiol 
group in the 5’′end were used. In addition, peptide was also included to compare with OPCs in the 
same ELISA assay. Thiol or amino groups of the OPCs were used for attachment to the ELISA 
microplate. For amino groups in basic conditions, ELISA microplates (Costar Corp, DNA-bindTM  
N-oxysuccinimide surface) were used as described [20]. For thiol groups microplates from Thermo 
Scientific Nunc ImmobilizerTM Amino Surface were used. 
Immunological assays were performed at 25 and 250 pmol/well. In DNA-bindTM microplates, 
peptide, duplex and OPC were dissolved in 50 mM Na2HPO4 1 mM EDTA (pH 8.5) binding buffer 
whereas in Nunc microplates, peptide, duplex OPC and single OPC were dissolved in 10 mM 
phosphate buffer with 150 mM NaCl (pH 7) binding buffer. The rest of the protocol was the same for 
both ELISAs. Briefly, 100 µL of the solutions was added to each microplate wells and incubated 
overnight at 4 °C. In order to estimate the background reading, each plate contained control wells that 
included all reagents except the serum sample, while to evaluate non-specific reactions of human 
serum, control wells included all reagents except peptide, duplex or OPC. For blank controls, wells 
were coupled with 2 µg BSA/well. After incubation, the plates were blocked with 2% BSA in binding 
buffer for 1 h at room temperature. Human serum was diluted 50-fold in RIA buffer (1% BSA,  
350 mM NaCl, 10 mMTris HCl (pH 7.6) 1% vol/vol Triton X-100, 0.5 wt %/vol Na-deoxycholate, 
0.1% SDS) supplemented with 10% fetal bovine serum. 100 µL/well was added and incubated for  
1.5 h at room temperature. After washing 6 times with PBS/0.05% Tween-20, 100 µL/well of 
antihuman IgG conjugated to peroxidase diluted 1:1,000 in RIA buffer was added. After incubation for 
1 h at room temperature, the plate was washed six times with PBS/0.05% Tween-20, and bound 
antibodies were detected with o-phenylenediamine (OPD, Sigma Aldrich, St Louis, MO, USA). The 
plates were incubated at room temperature for 30 min. The reaction was stopped with  
50 µL of 2 N H2SO4 per well, and absorbance values were measured at a wavelength at 492 nm. All 
human serum samples were tested in duplicate. Control sera were also included to monitor inter-and 
intra-assay variation. 
4. Conclusions  
Biomolecule conjugation has allowed the preparation of novel chimeric molecules with properties 
than cannot be achieved from single biomolecules. One of the areas of interest is the use of 
oligonucleotides for the binding of multiple antigens to solid supports; using DNA surfaces as 
immobilization matrices. The DNA-directed immobilization method has been successfully used for the 
patterning of surfaces with specific antibodies [38] but no data is available for the DNA-directed 
immobilization of peptide antigens. In order to achieve this goal, the development of methodology for 
the synthesis of oligonucleotide-peptide conjugates is needed. Peptides and oligonucleotides are rich in 
functional groups and the coupling between them is challenging. Here we described the synthesis of 
OPCs. Conjugation was achieved using a large and complex peptide that was previously designed and 
tested for RA diagnosis. We show that post-synthetic and solid-phase methods are suitable approaches 
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to prepare these OPCs. Solid-phase synthesis was more adequate because it is more straightforward, 
and the yield was slightly better. Nevertheless, the strong acid treatment that is required makes this 
method suitable only for DNA or RNA pyrimidine sequences. Given that RNA is more stable to acids 
than DNA, it remains to be seen whether acid treatments can also be used for RNA sequences with 
purine nucleosides. 
Here we described the preparation of an OPC carrying a disulfide bond in a polythymidine 
sequence. Cyclization was accomplished using a similar procedure as the one described for peptides 
after solid-phase synthesis of the corresponding linear OPC. 
Finally, OPCs prepared were tested in ELISAs for RA diagnosis. Two formats, single OPCs and 
duplex OPCs were similarly recognized by RA patient sera containing ACPAs. Specific 
immobilization of duplex OPCs on the ELISA plate was more efficient using thiol than amino groups. 
The findings presented here can be extended to the preparation of conjugates of triplex-forming 
oligonucleotides as these usually comprised polypyrimidine sequences. 
Supplementary Materials 
Supplementary materials can be accessed at: http://www.mdpi.com/1420-3049/17/12/13825/s1. 
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